Clinical Trial Update: Triple vs Dual Lipid-Lowering Therapy for LDL-C Reduction in Acute Coronary Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial comparing triple versus dual lipid-lowering therapy to reduce LDL-C in patients with acute coronary syndrome; not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndromes
• Hypercholesterolemia

Snippet

Sponsor: Punjab Institute of Cardology | Conditions: Acute Coronary Syndromes (ACS), Hypercholesterolemia | Phase 4 | Status: NOT_YET_RECRUITING